July 10, 2026

Ateganosine Plus Cemiplimab Shows Promising Activity in Advanced Lung Cancer

Clinical Trails /

Interim results from the phase 2 THIO-101 trial show that the investigational drug ateganosine (THIO), followed by the PD-1 inhibitor cemiplimab (Libtayo), achieved a 90.5% disease control rate in heavily pretreated patients with advanced non-small cell lung cancer (NSCLC). Among 21 patients evaluated, 19 experienced either a complete response, partial response, or stable disease. This […]

Ateganosine Plus Cemiplimab Shows Promising Activity in Advanced Lung Cancer Read More »

Zoldonrasib Combinations Show Strong Early Results in RAS G12D Pancreatic Cancer

Treatment /

New data show that zoldonrasib (RMC-9805), an oral RAS G12D-targeted therapy, produced promising results in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) carrying a RAS G12D mutation. In previously untreated patients, zoldonrasib combined with modified FOLFIRINOX achieved an objective response rate of 82%, while the combination with gemcitabine plus nab-paclitaxel reached 61%. Disease control rates

Zoldonrasib Combinations Show Strong Early Results in RAS G12D Pancreatic Cancer Read More »

Updated Analysis Suggests DCVax-L Offers Greater Survival Benefit in Glioblastoma

Treatment /

New data suggest that the survival benefit of DCVax-L for patients with glioblastoma (GBM) is greater than previously reported. The original phase 3 analysis showed that DCVax-L improved median overall survival by 2.8 months. However, a new analysis using individual patient data from three randomized clinical trials found that the actual survival benefit ranged from

Updated Analysis Suggests DCVax-L Offers Greater Survival Benefit in Glioblastoma Read More »

Ensartinib Significantly Reduces Recurrence Risk in ALK-Positive Lung Cancer After Surgery

Treatment /

Results from the phase 3 ELEVATE trial show that ensartinib (Ensacove) significantly reduced the risk of cancer recurrence in patients with completely resected stage IB to IIIB ALK-positive non-small cell lung cancer (NSCLC) after chemotherapy. Among patients with stage II to IIIB disease, the 24-month disease-free survival (DFS) rate was 86.4% with ensartinib, compared with

Ensartinib Significantly Reduces Recurrence Risk in ALK-Positive Lung Cancer After Surgery Read More »